株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

経皮パッチの世界市場およびパイプラインの将来展望

Global Transdermal Patch Market & Clinical Pipeline Outlook 2022

発行 KuicK Research 商品コード 324804
出版日 ページ情報 英文 260 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=113.76円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
経皮パッチの世界市場およびパイプラインの将来展望 Global Transdermal Patch Market & Clinical Pipeline Outlook 2022
出版日: 2017年03月01日 ページ情報: 英文 260 Pages
概要

当レポートでは、世界の経皮パッチ市場について分析し、経皮パッチの特性や作用機序、パイプライン製品の現在の開発状況、全体的な市場構造・動向、上市済み製品 の販売状況、主要企業のプロファイル、今後の市場の方向性といった情報をお届けいたします。

第1章 経皮パッチの概略

第2章 経皮パッチの分類

  • 単層式/多層式の薬剤入り接着剤
  • リザーバつき経皮パッチ
  • 基質ベースの経皮パッチ
  • 蒸気パッチ
  • アクティブ/パッシブパッチ

第3章 なぜ、経皮パッチのニーズが存在しているのか?

第4章 経皮パッチのドラッグデリバリ (薬物送達) メカニズム

  • 経皮的治療方法の特徴
  • 経皮パッチの構成要素
  • 乗り物酔い/ニコチン/避妊用経皮パッチ

第5章 経皮パッチと、従来型のドラッグデリバリ方式の対比

第6章 世界の経皮パッチ市場の概況

  • 世界市場のシナリオ
  • 地域別の動向

第7章 経皮パッチの臨床パイプラインの概況

  • 相 (フェーズ) 別
  • 地域/国別
  • 薬剤クラス/分子別
  • 企業別
  • 希用薬・ファストトラック医薬品の状況
  • 作用機序別

第8章 経皮パッチ市場のダイナミクス

  • 市場にプラスに働いている指標
  • 実用化に際しての課題

第9章 世界の経皮パッチ市場の将来展望

第10章 経皮パッチの治験動向

  • 不明
  • 研究段階
  • 前臨床段階
  • 臨床段階
  • 第I相
  • 第I/II相
  • 第II相
  • 第III相
  • 認証前
  • 認証済み

第11章 上市済みの経皮パッチ:企業別・適応症別・相別

第12章 競争環境

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

"Global Transdermal Patch Market & Clinical Pipeline Outlook 2022" report discusses the ongoing clinical and non-clinical parameters with respect to development of global transdermal patch market. Report highlights the need for integration of transdermal patches in existing drug delivery methodology available to pharmaceutical companies. Currently there 40 transdermal patches available in the market and more than 70 patches are in clinical pipeline.

Transdermal patches have made their place in global market in past few decades as an alternative to conventional therapeutic for various disease indications. Systemic drug delivery could be achieved by oral and prenatal methods but they have several limitations due to which many patients often find them inconvenient. Pharmaceutical companies have identified these problems as an opportunity to develop transdermal patches for generating significant revenues. This problem was identified early and advancements in biotechnology helped in the introduction of transdermal patches in global market. Nowadays, they are available for different disease indications and generally found suitable for large number of people having different disease indications. As a result, numbers of users are escalating at tremendous rates which are steadily increasing the global size.

Transdermal patches are widely accepted among physicians and patients due to their non-invasive, pain free and easy administration. In recent years, the growth of transdermal patch market has increased and expected to increase significantly in coming years. Higher investments in research and development could be attributed to the success of transdermal patch market. Number of disease indication treated by them is increasing steadily leading to higher market penetration. Every year various transdermal patches are introduced in globally leading to increased market size.

Transdermal patches presently donning the market are formulated in accordance with requirement of the medicinal therapy. They can be worn for as low as 8 hours to as long as 7 days depending on the therapeutic indication. These patches are secured with adhesives, which are designed to adhere comfortably to the skin which in turn allows a patient to use the patches for as long as is indicated by his or her physician. Transdermal drug delivery provides excellent control of the rate of delivery directly into the bloodstream. It also offers a predictable pharmacokinetic profile and constant drug levels over extended periods of time without the extreme peak/trough fluctuations inherent in oral administration with the inherent power of discontinuation of therapy immediately by simply removing the patch.

Strong clinical pipeline could be observed in case of transdermal patches which reflect the interest of pharmaceutical companies in this segment. Before marketing approval they have to undergo strict testing and checking for various qualitative parameters. They must be stable, chemically unreactive, hypo allergic, nontoxic and easy to manufacture. High throughput methods are expected to increase the suitable polymer screening rates along with reduced time consumption. Bioequivalence of therapeutic in transdermal patch with same drug administrated via different route have known efficacy must be shown. Similarly, independent of patch type they must show bioequivalence in clinical trials before getting marketing approval from medical regulatory authorities. Various products are at different stages of clinical trials which will be introduced in global market in coming years.

"Global Transdermal Patch Market & Clinical Pipeline Outlook 2022" report highlights:

  • Introduction & Classification of Transdermal Patch
  • Mechanism of Transdermal Patch Drug Delivery
  • Transdermal Patch v/s Traditional Drug Delivery Methods
  • Global Transdermal Patch Clinical Pipeline Overview
  • Marketed Transdermal Patch Clinical Insight by Company, Indication & Phase
  • Global Transdermal Patch Market Future Prospects

Table of Contents

1. Introduction to Transdermal Patch

2. Classification of Transdermal Patches

  • 2.1 Single/ Multiple-Layer Drug-in-Adhesive
  • 2.2 Reservoir Transdermal Patches
  • 2.3 Matrix Based Transdermal Patches
  • 2.4 Vapor Patch
  • 2.5 Active and Passive Patch

3. Why There Exist Need for Transdermal Patches?

4. Mechanism of Transdermal Patch Drug Delivery

  • 4.1 Properties of Transdermal Therapeutics
  • 4.2 Components of Transdermal Patch
  • 4.3 Mechanism of Motion Sickness, Nicotine & Female Contraceptive Transdermal Patch

5. Transdermal Patch v/s Traditional Drug Delivery Methods

6. Global Transdermal Patch Market Outlook

  • 6.1 Global Market Scenario
  • 6.2 Regional Trends

7. Global Transdermal Patch Clinical Pipeline Overview

  • 7.1 By Phase
  • 7.2 By Region/Country
  • 7.3 By Drug Class/Molecule
  • 7.4 By Company
  • 7.5 By Orphan & Fast Track Status
  • 7.6 By Mode of Action

8. Global Transdermal Patch Market Dynamics

  • 8.1 Favorable Market Parameters
  • 8.2 Commercialization Challenges

9. Global Transdermal Patch Market Future Prospects

10. Global Transdermal Patch Clinical Insight

  • 10.1 Unknown
  • 10.2 Research
  • 10.3 Preclinical
  • 10.4 Clinical
  • 10.5 Phase-I
  • 10.6 Phase-I/II
  • 10.7 Phase-II
  • 10.8 Phase-II/III
  • 10.9 Phase-III
  • 10.10 Preregistration
  • 10.11 Registered

11. Marketed Transdermal Patch Clinical Insight by Company, Indication & Phase

12. Competitive Landscape

  • 12.1 3M Pharmaceuticals
  • 12.2 Acrux
  • 12.3 Agile Therapeutics
  • 12.4 Allergan
  • 12.5 ANI Pharmaceuticals
  • 12.6 Antares Pharma
  • 12.7 Bayer HealthCare Pharmaceuticals
  • 12.8 Corium International
  • 12.9 Chase Pharmaceuticals
  • 12.10 DURECT Corporation
  • 12.11 Endo Pharmaceuticals
  • 12.12 Fempharm
  • 12.13 Hisamitsu Pharmaceutical
  • 12.14 Immune Pharmaceuticals
  • 12.15 Imprimis Pharmaceuticals
  • 12.16 Ipsen Bioscience
  • 12.17 Johnson & Johnson
  • 12.18 LaSalle Laboratories
  • 12.19 Lavipharm-increase
  • 12.20 MINRAD International
  • 12.21 NeurogesX
  • 12.22 Noven Pharmaceuticals
  • 12.23 NuPathe
  • 12.24 Nuvo Research
  • 12.25 Novartis
  • 12.26 Pain Therapeutics
  • 12.27 ProStrakan
  • 12.28 Purdue Pharma
  • 12.29 Sanofi
  • 12.30 Scilex Pharmaceuticals
  • 12.31 Senju Pharmaceutical
  • 12.32 Somerset Pharmaceuticals
  • 12.33 Teikoku Seiyaku
  • 12.34 Therapeutic Discovery Corporation
  • 12.35 Transdermal Delivery Solutions Corp
  • 12.36 UCB-full form
  • 12.37 Xel Pharmaceuticals
  • 12.38 Zosano Pharma

List of Figures

  • Figure 1-1: Steps Involved in Transdermal Permeation
  • Figure 1-2: Ideal Properties of Transdermal Patch
  • Figure 2-1: Types of Commercially Available Transdermal Patch
  • Figure 4-1: Properties of Transdermal Therapeutics
  • Figure 4-2: Components of Transdermal Patch
  • Figure 4-3: Types of Permeation Enhancers
  • Figure 4-4: Schematic Representation of Iontophoresis
  • Figure 4-5: Mechanism of Scopolamine Transdermal Patch
  • Figure 4-6: Mechanism of Nicotine Transdermal Patch
  • Figure 4-7: Mechanism of Female Contraceptive Transdermal Patch
  • Figure 5-1: Issues with Traditional Drug Delivery Methods
  • Figure 5-2: Advantages of Transdermal Patch
  • Figure 5-3: Consistent Drug Supply by Transdermal Patch
  • Figure 6-1: Global - Transdermal Patch Market Opportunity (US$ Billion), 2016-2022
  • Figure 7-1: Global - Transdermal Patch Pipeline by Phase (%), 2017 till 2022
  • Figure 7-2: Global - Transdermal Patch Pipeline by Phase (Number), 2017 till 2022
  • Figure 7-3: Global - Transdermal Patch Pipeline by Phase (%), 2017 till 2022
  • Figure 7-4: Global - Transdermal Patch Pipeline by Phase (Number), 2017 till 2022
  • Figure 7-5: Global - Transdermal Patch Pipeline by Region (%), 2017 till 2022
  • Figure 7-6: Global - Transdermal Patch Pipeline by Country (%), 2017 till 2022
  • Figure 7-7: Global - Transdermal Patch Pipeline by Drug Class/Molecule (%), 2017 till 2022
  • Figure 7-8: Global - Transdermal Patch Pipeline by Company (%), 2017 till 2022
  • Figure 7-9: Global - Transdermal Patch Pipeline by Ophan & Fast Track Status (%), 2017 till 2022
  • Figure 7-10: Global - Transdermal Patch Pipeline by Mode of Action (%), 2017 till 2022
  • Figure 8-1: Drivers for Transdermal Patch
  • Figure 8-2: Transdermal Patch Market Commercialization Challenges
  • Figure 12-1: Acrux Clinical Pipeline
  • Figure 12-2: Agile Therapeutics Clinical Pipeline
  • Figure 12-3: Antares Pharma Clinical Pipeline
  • Figure 12-4: Corium International Clinical Pipeline
  • Figure 12-5: Durect Corporation Clinical Pipeline
  • Figure 12-6: Endo Pharmaceuticals Clinical Pipeline
  • Figure 12-7: Immune Pharmaceuticals Clinical Pipeline
  • Figure 12-8: Novartis Clinical Pipeline
  • Figure 12-9: Senju Pharmaceuticals Clinical Pipeline
  • Figure 12-10: Xel Pharamaceuticals Clinical Pipeline
  • Figure 12-11: Zosano Pharma Clinical Pipeline

List of Tables

  • Table 2-1: Differences between Active & Passive Transdermal Patches
  • Table 4-1: Transdermal Patches for Various Disease Indications
  • Table 12-1: Pain Therapeutics Clinical Pipeline
Back to Top